eTheRNA immunotherapies
Signal active
Organization
Contact Information
Overview
eTheRNA immunotherapies' mission is to help patients to overcome certain cancers and infectious diseases by developing novel immunotherapies that target the fundamental role of dendritic cells in the human immune system. eTheRNA’s proprietary mRNA-based TriMix technology boosts dendritic cells leading to a more comprehensive, sustainable and safer enhancement of the patient’s immune system than any other similar approach investigated until now.
About
Industries
Biotechnology, Health Care, Medical Device, Therapeutics
Founded
2013
Employees
51-100
Headquarters locations
Europe
Social
N/A
Profile Resume
eTheRNA immunotherapies headquartered in Europe, operates in the Biotechnology, Health Care, Medical Device, Therapeutics sector. The company focuses on Biotechnology and has secured $9.0B in funding across 80 round(s). With a team of 51-100 employees, eTheRNA immunotherapies is actively contributing to advancements in Biotechnology. Their latest funding round, Series A - eTheRNA immunotherapies, raised $26.6M. Discover more about their projects, partnerships, and impact on our platform.
Funding Rounds
Funding rounds
5
Investors
4
Lead Investors
0
Total Funding Amount
$111.9M
Details
3
eTheRNA immunotherapies has raised a total of $111.9M in funding over 3 rounds.
| Announcement date | Transaction name | Number of Investors | Money raised | Lead Investor |
|---|---|---|---|---|
| 2020 | Early Stage Venture | 38.3M | ||
| 2022 | Early Stage Venture | 38.9M | ||
| 2016 | Early Stage Venture | 26.6M |
Investors
eTheRNA immunotherapies is funded by 31 investors.
| Investor Name | Lead Investor | Funding Round | Partners |
|---|---|---|---|
| PMV | - | FUNDING ROUND - PMV | 26.6M |
| Omega Funds | - | FUNDING ROUND - Omega Funds | 26.6M |
| eTheRNA immunotherapies | - | FUNDING ROUND - eTheRNA immunotherapies | 26.6M |
| Boehringer Ingelheim Venture Fund | - | FUNDING ROUND - Boehringer Ingelheim Venture Fund | 26.6M |
Recent Activity
There is no recent news or activity for this profile.